156 related articles for article (PubMed ID: 22780914)
21. Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).
Verhoest PR; Basak AS; Parikh V; Hayward M; Kauffman GW; Paradis V; McHardy SF; McLean S; Grimwood S; Schmidt AW; Vanase-Frawley M; Freeman J; Van Deusen J; Cox L; Wong D; Liras S
J Med Chem; 2011 Aug; 54(16):5868-77. PubMed ID: 21744827
[TBL] [Abstract][Full Text] [Related]
22. A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
Allerton CM; Barber CG; Beaumont KC; Brown DG; Cole SM; Ellis D; Lane CA; Maw GN; Mount NM; Rawson DJ; Robinson CM; Street SD; Summerhill NW
J Med Chem; 2006 Jun; 49(12):3581-94. PubMed ID: 16759100
[TBL] [Abstract][Full Text] [Related]
23. Cyclic guanidines: synthesis and antiplatelet activity of 4,6,7,8-tetrahydro-1H-imidazo[1,2-a]pyrazolo[3,4-d]pyrimidin-7-ones and 1,4,6,7,8,9-hexahydropyrazolo [3',4':4,5]pyrimido[2,1-c] [1,2,4]triazin-7-ones.
Ferroni R; Simoni D; Orlandini P; Bardi A; Franze GP; Guarneri M
Arzneimittelforschung; 1990 Dec; 40(12):1328-31. PubMed ID: 2095128
[TBL] [Abstract][Full Text] [Related]
24. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides.
Rueeger H; Lueoend R; Rogel O; Rondeau JM; Möbitz H; Machauer R; Jacobson L; Staufenbiel M; Desrayaud S; Neumann U
J Med Chem; 2012 Apr; 55(7):3364-86. PubMed ID: 22380629
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.
Wang G; Liu Z; Chen T; Wang Z; Yang H; Zheng M; Ren J; Tian G; Yang X; Li L; Li J; Suo J; Zhang R; Jiang X; Terrett NK; Shen J; Xu Y; Jiang H
J Med Chem; 2012 Dec; 55(23):10540-50. PubMed ID: 23137303
[TBL] [Abstract][Full Text] [Related]
26. Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Matsunaga N; Ora T; Ohyabu N; Nishigaki N; Imura Y; Igata Y; Matsui H; Motoyaji T; Tanaka T; Habuka N; Sogabe S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
J Med Chem; 2011 Dec; 54(24):8616-31. PubMed ID: 22074142
[TBL] [Abstract][Full Text] [Related]
27. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.
Zhang P; Jiang MY; Le ML; Zhang B; Zhou Q; Wu Y; Zhang C; Luo HB
Bioorg Med Chem Lett; 2020 Jul; 30(14):127254. PubMed ID: 32527553
[TBL] [Abstract][Full Text] [Related]
30. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.
Liang J; Zhang B; Labadie S; Ortwine DF; Vinogradova M; Kiefer JR; Gehling VS; Harmange JC; Cummings R; Lai T; Liao J; Zheng X; Liu Y; Gustafson A; Van der Porten E; Mao W; Liederer BM; Deshmukh G; Classon M; Trojer P; Dragovich PS; Murray L
Bioorg Med Chem Lett; 2016 Aug; 26(16):4036-41. PubMed ID: 27406798
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.
Li P; Zheng H; Zhao J; Zhang L; Yao W; Zhu H; Beard JD; Ida K; Lane W; Snell G; Sogabe S; Heyser CJ; Snyder GL; Hendrick JP; Vanover KE; Davis RE; Wennogle LP
J Med Chem; 2016 Feb; 59(3):1149-64. PubMed ID: 26789933
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
[TBL] [Abstract][Full Text] [Related]
33. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
35. Rhenium tricarbonyl core complexes of thymidine and uridine derivatives.
Wei L; Babich J; Eckelman WC; Zubieta J
Inorg Chem; 2005 Apr; 44(7):2198-209. PubMed ID: 15792454
[TBL] [Abstract][Full Text] [Related]
36. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
37. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
Almeida CB; Traina F; Lanaro C; Canalli AA; Saad ST; Costa FF; Conran N
Br J Haematol; 2008 Sep; 142(5):836-44. PubMed ID: 18564357
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
Mikami S; Kawasaki M; Ikeda S; Negoro N; Nakamura S; Nomura I; Ashizawa T; Kokubo H; Hoffman ID; Zou H; Oki H; Uchiyama N; Hiura Y; Miyamoto M; Itou Y; Nakashima M; Iwashita H; Taniguchi T
Chem Pharm Bull (Tokyo); 2017; 65(11):1058-1077. PubMed ID: 29093293
[TBL] [Abstract][Full Text] [Related]
39. Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis.
Wang H; Luo X; Ye M; Hou J; Robinson H; Ke H
J Med Chem; 2010 Feb; 53(4):1726-31. PubMed ID: 20121115
[TBL] [Abstract][Full Text] [Related]
40. Pyrrolidin-3-yl-N-methylbenzamides as potent histamine 3 receptor antagonists.
Zhou D; Gross JL; Sze JY; Adedoyin AB; Bowlby M; Di L; Platt BJ; Zhang G; Brandon N; Comery TA; Robichaud AJ
Bioorg Med Chem Lett; 2011 Oct; 21(19):5957-60. PubMed ID: 21843941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
